Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology.
Routine screening for monoclonal gammopathy of undetermined significance (MGUS) is not indicated. Despite this fact, MGUS is a common finding in medical practice. Almost all individuals diagnosed with MGUS represent incidental cases diagnosed when physicians order serum protein electrophoresis, immunofixation, or both, as part of the work-up of a number of common symptoms and laboratory abnormalities. In the absence of reliable molecular predictors of outcome, the detection of an early precursor state typically imposes a complex situation for the patient and the responsible physician-usually, it leads to a lot of questions that lack clear answers. In the past years, several novel insights have been gained in the area of multiple myeloma (MM) precursor disease. This review focuses on results from recent investigations and discusses implications for diagnostic work-up, clinical management, and patient counseling. More specifically, it sheds light on the following commonly asked questions by patients and physicians: i) what is the risk of progression from precursor to full-blown MM, and are there ways to risk-stratify patients?; ii) is MM always preceded by a precursor state, and is there anything that could or should be done to delay or prevent progression?; and iii) why do some individuals develop MM precursor diseases, and is there a reason to screen the family?
Multiple Myeloma Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. landgreo@mail.nih.gov
Ola
O
Landgren
D006801:Humans; D016130:Immunophenotyping; D018448:Models, Immunological; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000150:complications / Q000453:epidemiology* / Q000503:physiopathology*; D009101:Multiple Myeloma / Q000150:complications / Q000453:epidemiology* / Q000503:physiopathology*; D017410:Practice Guidelines as Topic; D012307:Risk Factors
Haematologica. 2006 Dec;91(12):1697-700
17145609
Blood. 2010 Aug 19;116(7):1056-9
20421448
Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):248-57
20709660
Cancer Res. 1987 Jun 1;47(11):2978-81
3567914
Methods Mol Med. 2005;113:5-24
15968091
Harvey Lect. 1960-1961;56:211-31
14004528
Blood. 1996 Jun 1;87(11):4762-9
8639847
Am J Med. 1978 May;64(5):814-26
645746
Leukemia. 2001 Aug;15(8):1274-6
11480571
Expert Rev Mol Diagn. 2010 May;10(4):465-80
20465501
J Clin Oncol. 2005 Sep 10;23(26):6333-8
16155016
Leukemia. 2008 Sep;22(9):1651-7
18668131
Leukemia. 2008 Dec;22(12):2280-4
18528420
N Engl J Med. 1980 Jun 12;302(24):1347-9
7374679
N Engl J Med. 2007 Jun 21;356(25):2582-90
17582068
Acta Oncol. 2000;39(7):823-7
11145440
N Engl J Med. 2006 Mar 30;354(13):1362-9
16571879
Mayo Clin Proc. 2007 Apr;82(4):428-34
17418070
Blood. 2010 Jun 17;115(24):4991-8
20299513
Blood. 2009 May 28;113(22):5412-7
19179464
Blood. 2005 Jan 1;105(1):317-23
15339850
Blood. 2002 Aug 15;100(4):1417-24
12149226
Br J Haematol. 1994 Jun;87(2):266-72
7947266
Best Pract Res Clin Haematol. 2007 Dec;20(4):597-612
18070708
Blood. 2002 Mar 15;99(6):2185-91
11877296
Clin Cancer Res. 2009 Sep 1;15(17):5369-78
19690192
Clin Cancer Res. 2009 May 1;15(9):3118-25
19366830
Environ Health Perspect. 2009 Apr;117(4):581-6
19440497
Blood. 2010 Oct 14;116(15):2651-5
20610813
Mayo Clin Proc. 2007 Dec;82(12):1468-73
18053453
Blood. 2009 May 28;113(22):5418-22
19234139
Blood. 2005 Aug 1;106(3):812-7
15855274
Br J Haematol. 2003 Jun;121(5):749-57
12780789
Nature. 1989 May 4;339(6219):58-61
2469964
Blood. 2003 Nov 15;102(10):3759-64
12881316
Curr Treat Options Oncol. 2000 Jun;1(2):119-26
12057049
Blood. 2008 Jan 15;111(2):785-9
17942755
Blood. 2009 Jun 18;113(25):6386-91
19387005
Blood. 2001 Nov 15;98(10):3082-6
11698294
J Bone Miner Res. 2004 Jan;19(1):25-30
14753733
Blood. 2009 Jul 23;114(4):785-90
19179466
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12885-90
18728182
Haematologica. 2009 Dec;94(12):1714-20
19608666
Int J Cancer. 2007;120 Suppl 12:40-61
17405120
N Engl J Med. 2002 Feb 21;346(8):564-9
11856795
Arch Intern Med. 1988 Sep;148(9):1963-5
2458080
Blood. 2009 Jul 23;114(4):791-5
19182202
Best Pract Res Clin Haematol. 2007 Dec;20(4):571-96
18070707
Haematologica. 2009 Jul;94(7):1024-8
19454499
J Clin Oncol. 2009 Sep 1;27(25):4197-203
19636021
Br J Haematol. 2005 Sep;130(5):729-32
16115129
Int J Cancer. 2006 Jun 15;118(12):3095-8
16395700
Br J Haematol. 2004 Sep;126(5):686-9
15327520
Leukemia. 2009 Oct;23(10):1691-7
19587704
Blood Rev. 2007 Sep;21(5):255-65
17367905
Br J Haematol. 2006 Oct;135(1):62-7
16925792
Leukemia. 2010 Jun;24(6):1121-7
20410922
Cancer Res. 2004 Feb 15;64(4):1546-58
14989251
Blood. 2008 Nov 1;112(9):3582-6
18559977
Blood. 2007 Oct 1;110(7):2586-92
17576818
Blood. 2006 Sep 1;108(5):1724-32
16705089
Cell. 2004 Jan 23;116(2):281-97
14744438
Clin Cancer Res. 2002 Jul;8(7):2210-6
12114422
APMIS. 2001 Nov;109(11):797-800
11900061
Leukemia. 2008 Feb;22(2):231-9
17972944
Am J Med. 1993 Jan;94(1):57-61
8420300